Supplemental data:

Association of ESA hypo-responsiveness and haemoglobin variability with mortality in hemodialysis patients

A. Kainz1,2, B. Mayer3, R. Kramar4, R. Oberbauer1,2,4

1- Department of Nephrology, Medical University of Vienna, Austria
2- Department of Nephrology, KH Elisabethinen, Linz, Austria
3- emergentec Biodevelopment GmbH, 1080 Vienna, Austria
4- Austrian Dialysis and Transplant Registry, Linz, Austria


All supplemental data are available for download as a single PDF document.

TABLES
FIGURES
Webtable 1 Webtable 1
Association of hemoglobin variability group with mortality in an unadjusted Cox model (reference group MM).

Webfigure 1a

Webfigure 1b

Webfigure 1c

Webfigure 1d 		Webfigure 1a b  c d

Hemoglobin values of patients vs administered ESA dose for each year during followup time

a: first year of treatment
b: second year of treatment
c: third year of treatment
d: fourth year of treatment
Webtable 2 Webtable 2
Association of hemoglobin variability group with mortality. Cox model is adjusted by age, vintage of dialysis, and sex.

Webfigure 2a

Webfigure 2b 		Webfigure 2a b

Hazard ratio of ESA dose levels (reference value 12500 U/week)

a: ESA hypo-responder
b: ESA responder
Webtable 3 Webtable 3
Association of hemoglobin variability group with mortality. Cox model is adjusted by age, vintage of dialysis, sex, and ESA response group.

Webfigure 3a

Webfigure 3b

Webfigure 3c 		Webfigure 3a  b  c

Dependency of hazard ratio of achieved hemoglobin levels for patients with baseline hemoglobin corresponding to

a: group L
b: group M
c: group H
Webtable 4 Webtable 4
Association of hemoglobin variability group with mortality. Cox model is adjusted by age, vintage of dialysis, sex, ESA response group, diabetes, and BMI. Missing BMI values were imputed by mulitple imputation through linear regression.

Webfigure 4a

Webfigure 4b Webfigure 4c 		Webfigure 4a  b  c

Dependency of hazard ratio of ESA dose levels for patients with baseline hemoglobin corresponding to

a: group L
b: group M
c: group H
Webfigure 5a

Webfigure 5b 		Webfigure 5a b

Dependency of hazard ratio of ESA dose levels for patients with

a: baseline hemoglobin ≤ 12 g/dl
b: baseline hemoglobin > 12 g/dl
Webfigure 6a

Webfigure 6b 		Webfigure 6a b

Dependency of hazard ratio of ESA dose levels for patients with

a: baseline hemoglobin ≤ 12 g/dl
b: baseline hemoglobin > 12 g/dl
Webfigure 7

 Webfigure 7

Hazard ratio for haemoglobin levels of incident patients stratified in groups of ESA responsiveness.
Webfigure 8

 Webfigure 8

Hazard ratio for ESA dose of incident patients stratified in groups of ESA responsiveness.
Webfigure 9

 Webfigure 9

Hazard ratio for haemoglobin levels of prevalent patients stratified in groups of ESA responsiveness.
Webfigure 10

 Webfigure 10

Hazard ratio for ESA dose of prevalent patients stratified in groups of ESA responsiveness.